XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.80

+0.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (7756)	11/18/1998 7:35:00 AM
From: Robert K.	Read Replies (1) of 17367

You are close. Cancers need a supply of blood to feed on and live. As the cancers get bigger (like a person), their food requirements increase. To grow, tumors need to grow blood vessels to keep that food supply coming. heparin and such are a requirement to grow blood vessels. Since bpi and analogs tend to neutralize heparin, then the tumors are unsuccessful (in general) in growing new blood vessels and they starve to death.(or their growth is stunted). This allows time for the natural systems and or cytotoxic drugs to finish the tumors off. HOWEVER, the problem with angiogenesis and anti-angiogenic drugs is that we NEED some angiogensis to live. For instance the heart needs to grow blood vessels or we die. SOOOO, the trick is to have a short treatment or to find a anti-angiogenic product that is angio-selective (I may have just coined that word). NOW, there are probably 30 anti-angiogenic compounds in development. It is best to choose one that is SAFE, NATURAL, and SELECTIVE. AND that you CAN MANUFACTOR and have PATENTED. So then the question becomes what foots this bill. All IMO all disclaimers. I apologize if any inaccuracies. Please feel free to correct me.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next